secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269442
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio Q3 net loss $3.9M ($0.85/share); cash $10.7M; INB-619/100 updates
------------------------------------------------------------------------

- Net loss of $3.9M in Q3 2025 vs $7.1M in Q3 2024; basic and diluted EPS -$0.85 vs -$4.49.
- R&D expenses $2.1M (down from $3.3M); G&A $1.9M (down from $2.7M) due to cost-saving measures.
- Cash $10.7M as of Sep 30, 2025, up from $4.0M year-over-year.
- INB-619 preclinical data at ACR showed B cell elimination similar to blinatumomab/mosunetuzumab with minimal cytokine release.
- INB-100 Phase 1 trial expanded to The Ohio State University to accelerate enrollment; updated GBM data planned at SNO Nov 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312525269442/0001193125-25-269442-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312525269442/inab-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269442

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer